Business
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 14, 2023
Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, March 3, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"Conference Call and Webcast at 8:30AM Eastern Time\nNEW YORK, March 3, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, March 14, 2023, at 8:30 AM EST. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth-quarter 2022 financial results.\n\n \n \n \n \n \n \n\n \nThe webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 877-550-1858 and international listeners should dial 1-848-488-9160. All listeners should provide the operator with the conference call name \"Lucid Diagnostics Business Update Conference Call\" to join.\nFollowing the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.\nAbout Lucid Diagnostics\nLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. \nFor more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com.\nForward-Looking Statements\nThis press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical fact...